HYPERIUM

This brand name is authorized in Brazil, France, Malta, Turkey

Active ingredients

The drug HYPERIUM contains one active pharmaceutical ingredient (API):

1 Rilmenidine UNII 59QD64Q32M - RILMENIDINE PHOSPHATE

Rilmenidine is an imidazoline derivative used for the treatment of hypertension. Rilmenidine, an oxazoline compound with antihypertensive properties, acts on both medullary and peripheral vasomotor structures. Rilmenidine shows greater selectivity for imidazoline receptors than for cerebral alpha2-adrenergic receptors, distinguishing it from reference alpha2-agonists. In addition to a reduction in blood pressure, Rilmenidine has been shown to improve glucose tolerance, lipid risk factors, and insulin sensitivity.

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
HYPERIUM Tablet	Medicines Authority (MT)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
C02AC06	Rilmenidine	C Cardiovascular system → C02 Antihypertensives → C02A Antiadrenergic agents, centrally acting → C02AC Imidazoline receptor agonists
Discover more medicines within C02AC06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 531300702118318
Country: FR	Base de données publique des médicaments	Identifier(s): 62174246, 67541600
Country: MT	Medicines Authority	Identifier(s): MA066/01301
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8699552010524